Skip to content

MAZE MAZE EBITDA margin

EBITDA margin at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
40.1%+36.9pp
Septerna, Inc. logo
Septerna, Inc.SEPN
-74.8%-37.3pp
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
-572.1%-593pp
Zymeworks logo
ZymeworksZYME
-132.6%+10.5pp
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
-427.3%+42.6pp
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
2.2%+1.1pp

Other financials

Income statement

See full
Revenue$20.0M
Operating income-$26.6M+25.0%
Net income-$24.2M+26.2%
EPS (diluted)-$0.45+60.9%

Balance sheet

See full
Cash & equivalents$198.8M-32.5%
Total debt$61.2M+137%
Total equity$341.7M+17.0%
Total assets$419.7M+26.1%

Cash flow

See full
Operating cash flow-$39.1M-32.5%
CapEx$93.0K-68.9%
Free cash flow-$39.2M-31.5%

Valuation

See full
Market cap$1.48B+201%
Enterprise value$1.34B
P/S7.9×

Profitability

See full
Operating margin-71.5%
Net margin-65.4%
FCF margin-65.1%

Returns & leverage

See full
Return on equity-38.7%
Debt / equity0.2×+0.1×
Current ratio17.9×+1.8×